- Home
- LSTA vs RNXT Comparison
LSTA vs RNXT Comparison
Compare LSTA & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- RNXT
- Stock Information
- Founded
- LSTA 1980
- RNXT 2012
- Country
- LSTA United States
- RNXT United States
- Employees
- LSTA N/A
- RNXT N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- LSTA Health Care
- RNXT Health Care
- Exchange
- LSTA Nasdaq
- RNXT Nasdaq
- Market Cap
- LSTA 24.1M
- RNXT 44.6M
- IPO Year
- LSTA N/A
- RNXT 2021
- Fundamental
- Price
- LSTA $2.61
- RNXT $1.36
- Analyst Decision
- LSTA Strong Buy
- RNXT Strong Buy
- Analyst Count
- LSTA 1
- RNXT 2
- Target Price
- LSTA $15.00
- RNXT $7.25
- AVG Volume (30 Days)
- LSTA 15.8K
- RNXT 147.2K
- Earning Date
- LSTA 08-11-2025
- RNXT 08-12-2025
- Dividend Yield
- LSTA N/A
- RNXT N/A
- EPS Growth
- LSTA N/A
- RNXT N/A
- EPS
- LSTA N/A
- RNXT N/A
- Revenue
- LSTA $1,000,000.00
- RNXT $240,000.00
- Revenue This Year
- LSTA N/A
- RNXT $3,186.05
- Revenue Next Year
- LSTA N/A
- RNXT $291.93
- P/E Ratio
- LSTA N/A
- RNXT N/A
- Revenue Growth
- LSTA N/A
- RNXT N/A
- 52 Week Low
- LSTA $1.87
- RNXT $0.75
- 52 Week High
- LSTA $4.20
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- LSTA 50.61
- RNXT 55.76
- Support Level
- LSTA $2.36
- RNXT $1.27
- Resistance Level
- LSTA $3.07
- RNXT $1.42
- Average True Range (ATR)
- LSTA 0.23
- RNXT 0.07
- MACD
- LSTA 0.02
- RNXT -0.02
- Stochastic Oscillator
- LSTA 37.50
- RNXT 62.50
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.